Intravenous iron dextran as a component of anemia management in chronic kidney disease: A report of safety and efficacy

International Journal of Nephrology

Volumn 2013, Issue , 2013, Pages

  Yessayan, Lenar ^a   Sandhu, Ankur ^b   Besarab, Anatole ^a   Yessayan, Alexy ^c   Frinak, Stan ^a   Zasuwa, Gerard ^a   Yee, Jerry ^a  

^a HENRY FORD HOSPITAL   (United States)

^b St Alexius Medical Center   (United States)

^c Statberrycom   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84876591437     PISSN: 2090214X     EISSN: 20902158     Source Type: Journal    
DOI: 10.1155/2013/703038     Document Type: Article

References (49)

1. Fishbane S., Frei G. L., Maesaka J., Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. American Journal of Kidney Diseases 1995 26 1 41 46 2-s2.0-0029055192
2. Fudin R., Jaichenko J., Shostak A., Bennett M., Gotloib L., Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 1998 79 3 299 305 2-s2.0-0031805697 10.1159/000045053 (Pubitemid 28310335)
3. Macdougall I. C., Tucker B., Thompson J., Tomson C. R. V., Baker L. R. I., Raine A. E. G., A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney International 1996 50 5 1694 1699 2-s2.0-0029952883 (Pubitemid 26364277)
4. Andrews N. C., Disorders of iron metabolism. The New England Journal of Medicine 1999 341 26 1986 1995 2-s2.0-0033599057 10.1056/NEJM199912233412607 (Pubitemid 30010408)
5. Ganz T., Molecular control of iron transport. Journal of the American Society of Nephrology 2007 18 2 394 400 2-s2.0-33846650973 10.1681/ASN. 2006070802 (Pubitemid 46193304)
6. Kooistra M. P., Niemantsverdriet E. C., Van Es A., Mol-Beermann N. M., Struyvenberg A., Marx J. J. M., Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium. Nephrology Dialysis Transplantation 1998 13 1 82 88 2-s2.0-0031962827 10.1093/ndt/13.1.82 (Pubitemid 28033584)
7. Maslovsky I., Intravenous iron in a primary-care clinic. American Journal of Hematology 2005 78 4 261 264 2-s2.0-16344381158 10.1002/ajh.20271 (Pubitemid 40471117)
8. Nemeth E., Tuttle M. S., Powelson J., Vaughn M. D., Donovan A., Ward D. M., Ganz T., Kaplan J., Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004 306 5704 2090 2093 2-s2.0-10844258104 10.1126/science.1104742 (Pubitemid 40007660)
9. Chandler G., Harchowal J., Macdougall I. C., Intravenous iron sucrose: establishing a safe dose. American Journal of Kidney Diseases 2001 38 5 988 991 2-s2.0-0034747961 (Pubitemid 33022176)
10. Folkert V. W., Michael B., Agarwal R., Coyne D. W., Dahl N., Myirski P., Warnock D. G., Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (≥250 mg) administration. American Journal of Kidney Diseases 2003 41 3 651 657 2-s2.0-0037374639 10.1053/ajkd.2003.50141 (Pubitemid 36278383)
11. Blaustein D. A., Schwenk M. H., Chattopadhyay J., Singh H., Daoui R., Gadh R., Avram M. M., The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease. Kidney International 2003 87 S72 S77 2-s2.0-0142200417 (Pubitemid 37315511)
12. Blaustein D. A., Schwenk M. H., Chattopadhyay J., Avram M. M., Recent experience with high-dose intravenous iron administration. Kidney International 2006 70 104 S26 S29 2-s2.0-33751081799 10.1038/sj.ki.5001973 (Pubitemid 44764124)
13. Atalay H., Solak Y., Acar K., Govec N., Turk S., Safety profiles of total dose infusion of low-molecular-weight iron dextran and high-dose iron sucrose in renal patients. Hemodialysis International 2011 15 3 374 378 2-s2.0-79959979279 10.1111/j.1542-4758.2011.00550.x
14. Anuradha S., Singh N. P., Agarwal S. K., Total dose infusion iron dextran therapy in predialysis chronic renal failure patients. Renal Failure 2002 24 3 307 313 2-s2.0-0036022105 10.1081/JDI-120005364 (Pubitemid 34839951)
15. Hamstra R. D., Block M. H., Schocket A. L., Intravenous iron dextran in clinical medicine. Journal of the American Medical Association 1980 243 17 1726 1731 2-s2.0-0018898174 10.1001/jama.243.17.1726 (Pubitemid 10148807)
16. Auerbach M., Rodgers G. M., Intravenous iron. The New England Journal of Medicine 2007 357 1 93 94 2-s2.0-34347381712 10.1056/NEJMc070203 (Pubitemid 47026766)
17. Chertow G. M., Mason P. D., Vaage-Nilsen O., Ahlmén J., On the relative safety of parenteral iron formulations. Nephrology Dialysis Transplantation 2004 19 6 1571 1575 2-s2.0-2942715132 10.1093/ndt/gfh185 (Pubitemid 38796422)
18. Chertow G. M., Mason P. D., Vaage-Nilsen O., Ahlmén J., Update on adverse drug events associated with parenteral iron. Nephrology Dialysis Transplantation 2006 21 2 378 382 2-s2.0-31544444964 10.1093/ndt/gfi253 (Pubitemid 43159991)
19. Fletes R., Lazarus J. M., Gage J., Chertow G. M., Suspected iron dextran-related adverse drug events in hemodialysis patients. American Journal of Kidney Diseases 2001 37 4 743 749 2-s2.0-0035057037 (Pubitemid 32268035)
20. McCarthy J. T., Regnier C. E., Loebertmann C. L., Bergstralh E. J., Adverse events in chronic hemodialysis patients receiving intravenous iron dextran-a comparison of two products. American Journal of Nephrology 2000 20 6 455 462 2-s2.0-0034525862 10.1159/000046199 (Pubitemid 32037529)
21. Critchley J., Adverse events associated with intravenous iron infusion (low molecular weight iron dextran and iron sucrose): a systematic review. Transfusion Alternatives in Transfusion Medicine 2007 9 8 36
22. Eichbaum Q., Foran S., Dzik S., Is iron gluconate really safer than iron dextran? Blood 2003 101 9 3756 3757 2-s2.0-0038542810 10.1182/blood-2003-02-0360 (Pubitemid 36857973)
23. Infed (Prescribing Information) 2009 Morristown, NJ, USA Watson Pharma
24. Dexferrum (Prescribing Information) 2010 Shirley, NY, USA American Regent Laboratories
25. Ferrlicit (Prescribing Information) 2010 Bridgewater, NJ, USA Sanofi-Aventis US
26. Venofer (Prescribing Information) 2007 Shirley, NY, USA American Regent laboratories
27. Feraheme (Prescribing Information) 2009 Lexington, Mass, USA AMAG Pharmaceuticals
28. Besarab A., Amin N., Ahsan M., Vogel S. E., Zazuwa G., Frinak S., Zazra J. J., Anandan J. V., Gupta A., Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. Journal of the American Society of Nephrology 2000 11 3 530 538 2-s2.0-0034088831 (Pubitemid 30115083)
29. Senger J. M., Weiss R. J., Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment. ANNA Journal 1996 23 3 319 325 2-s2.0-0030159767
30. Komolafe J. O., Kuti O., Ijadunola K. T., Ogunniyi S. O., A comparative study between intramuscular iron dextran and oral ferrous sulphate in the treatment of iron deficiency anaemia in pregnancy. Journal of Obstetrics and Gynaecology 2003 23 6 628 631 2-s2.0-0344826528 10.1080/01443610310001604394 (Pubitemid 37475900)
31. Auerbach M., Ballard H., Trout J. R., McIlwain M., Ackerman A., Bahrain H., Balan S., Barker L., Rana J., Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. Journal of Clinical Oncology 2004 22 7 1301 1307 2-s2.0-2142825053 10.1200/JCO.2004.08.119 (Pubitemid 41079845)
32. Dudrick S. J., O'Donnell J. J., Raleigh D. P., Rapid restoration of red blood cell mass in severely anemic surgical patients who refuse transfusion. Archives of Surgery 1985 120 6 721 727 2-s2.0-0021837323 (Pubitemid 15045907)
33. Ahsan N., Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study. Journal of the American Society of Nephrology 1998 9 4 664 668 2-s2.0-0031897948
34. Ahsan N., Infusion of total dose iron versus oral iron supplementation in ambulatory peritoneal dialysis patients: a prospective, cross-over trial. Advances in Peritoneal Dialysis 2000 16 80 84 2-s2.0-0033647567
35. Auerbach M., Witt D., Toler W., Fierstein M., Lerner R. G., Ballard H., Clinical use of the total dose intravenous infusion of iron dextran. Journal of Laboratory and Clinical Medicine 1988 111 5 566 570 2-s2.0-0023939763
36. Case G., Maintaining iron balance with total-dose infusion of intravenous iron dextran. ANNA Journal 1998 25 1 65 68 2-s2.0-0031990534
37. Auerbach M., Pappadakis J. A., Bahrain H., Auerbach S. A., Ballard H., Dahl N. V., Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. American Journal of Hematology 2011 86 10 860 862
38. NKF-KDOQI Clinical practice guidelines for anemia of chronic kidney disease: update 2000. American Journal of Kidney Diseases 2001 37 S182 S238
39. Auerbach M., Chaudhry M., Goldman H., Ballard H., Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial. Journal of Laboratory and Clinical Medicine 1998 131 3 257 260 2-s2.0-0032033665 (Pubitemid 28154050)
40. Auerbach M., Ballard H., Glaspy J., Clinical update: intravenous iron for anaemia. The Lancet 2007 369 9572 1502 1504 2-s2.0-34247615981 10.1016/S0140-6736(07)60689-8 (Pubitemid 46670290)
41. Bailie G. R., Clark J. A., Lane C. E., Lane P. L., Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrology Dialysis Transplantation 2005 20 7 1443 1449 2-s2.0-26044476338 10.1093/ndt/gfh820 (Pubitemid 41430619)
42. Faich G., Strobos J., Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. American Journal of Kidney Diseases 1999 33 3 464 570 2-s2.0-0033012811
43. Fishbane S., Ungureanu V. D., Maesaka J. K., Kaupke C. J., Lim V., Wish J., The safety of intravenous iron dextran in hemodialysis patients. American Journal of Kidney Diseases 1996 28 4 529 534 2-s2.0-0029795844 (Pubitemid 26337591)
44. Aggarwal H. K., Nand N., Singh S., Singh M., Hemant, Kaushik G., Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. Journal of Association of Physicians of India 2003 51 170 174 2-s2.0-0038656418 (Pubitemid 44227894)
45. Van Wyck D. B., Roppolo M., Martinez C. O., Mazey R. M., McMurray S., A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney International 2005 68 6 2846 2856 2-s2.0-32844465284 10.1111/j.1523-1755.2005.00758.x (Pubitemid 43251032)
46. Spinowitz B. S., Kausz A. T., Baptista J., Noble S. D., Sothinathan R., Bernardo M. V., Brenner L., Pereira B. J. G., Ferumoxytol for treating iron deficiency anemia in CKD. Journal of the American Society of Nephrology 2008 19 8 1599 1605 2-s2.0-49649099818 10.1681/ASN.2007101156
47. Agarwal R., Rizkala A. R., Bastani B., Kaskas M. O., Leehey D. J., Besarab A., A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. American Journal of Nephrology 2006 26 5 445 454 2-s2.0-33845774779 10.1159/000096174 (Pubitemid 44971735)
48. Charytan C., Qunibi W., Bailie G. R., Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron 2005 100 3 c55 c62 2-s2.0-20944449485 10.1159/000085049 (Pubitemid 40868986)
49. Stoves J., Inglis H., Newstead C. G., A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrology Dialysis Transplantation 2001 16 5 967 974 2-s2.0-0035003179 (Pubitemid 32440369)